AstraZeneca PLC (FRA:ZEG)

Germany flag Germany · Delayed Price · Currency is EUR
119.65
-1.75 (-1.44%)
At close: Jul 17, 2025, 10:00 PM CET
-16.88%
Market Cap185.06B
Revenue (ttm)50.87B
Net Income (ttm)7.19B
Shares Outn/a
EPS (ttm)4.60
PE Ratio25.74
Forward PE15.56
Dividend2.93 (2.42%)
Ex-Dividend DateFeb 20, 2025
Volume9,182
Average Volume13,885
Open119.90
Previous Close121.40
Day's Range119.65 - 121.50
52-Week Range111.00 - 158.20
Betan/a
RSI42.77
Earnings DateJul 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 94,300
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ZEG
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

AstraZeneca drug fails main goal of late-stage amyloidosis study

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of pro...

1 day ago - Reuters

Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug

AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India’s Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import an...

2 days ago - Business Upturn

Boost for AstraZeneca after successful trial of experimental blood pressure drug

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of hypertension.

3 days ago - This is Money

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

AstraZeneca Plc (NASDAQ: AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension. The trial included patient...

3 days ago - Benzinga

AstraZeneca shares show signs of life after successful trials of hypertension drug

Baxdostat trials showed immense promise for huge available market.

3 days ago - MarketWatch

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically mean...

3 days ago - Business Wire

AstraZeneca drug lowers high BP in late-stage study; shares rise

AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmake...

3 days ago - Reuters

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

5 days ago - Benzinga

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor

The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.

7 days ago - Evening Standard

Trump's Tariff Talk Keeps Markets on Edge

The FTSE 100 opened 22 points up this morning, despite threats of pharma and metals tariffs with stark implications for major stocks on the blue chip index. President Trump has said that an announceme...

8 days ago - OilPrice com

Artelo Biosciences Analyst See It As An Emerging Biotech

D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ: ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20 . Analyst Jason Kolbert wrote, “We continue ...

9 days ago - Benzinga

What's Behind The Recent Rally In IonQ Stock?

IonQ Inc. (NYSE: IONQ) shares climbed above $47.85 Tuesday morning before pulling back. The stock is still up approximately 13.5% over the past month. Here’s a look at what’s driving the recent price...

9 days ago - Benzinga

Why AstraZeneca Stock Got Thumped on Thursday

14 days ago - The Motley Fool

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

14 days ago - Investopedia

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment

In a high-stakes maneuver that could reshape the oncology landscape, AstraZeneca Plc (NASDAQ: AZN) is reportedly in talks with Summit Therapeutics Inc. (NASDAQ: SMMT) about a partnership worth up to...

14 days ago - Benzinga

Report: Summit in talks for $15 billion partnership with AstraZeneca

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca

14 days ago - CNBC Television

Report: Summit in talks for $15 billion partnership with AstraZeneca

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca

14 days ago - CNBC

Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports

Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.

14 days ago - Reuters

New London IPOs hit 28-year low amid AstraZeneca exit concerns

More than $100 billion worth of London-listed companies have announced or executed plans to move to New York in recent years.

14 days ago - Fortune

Wise Becomes the Latest UK Giant to Eye a Transatlantic Escape

Wise plans to move its primary listing from London to the US for better capital access, joining AstraZeneca and others in doing so. The post Wise Becomes the Latest UK Giant to Eye a Transatlantic Esc...

14 days ago - Investomania